At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Randomized Double-blind Double-dummy Placebo & Active-controlled Single-dose Six-way Crossover Study Evaluating Abuse Potential of NEURONTIN® Taken Orally With Oxycodone HCL in Healthy Non-drug Dependent Recreational Opioid Users
In Brief
A Phase 4 clinical trial evaluating gabapentin 600 mg, gabapentin 1200 mg, and 4 other interventions for Abuse Potential. Completed, enrolled 54 participants across 1 site.
Detailed Summary
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational opioid users.
Study Details
Timeline
Interventions
Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl